Pharmaceutical Executive-11-01-2017

Analysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods-and the realization that failures have their place in shaping the pipeline of tomorrow.

With its convergence of healthcare talent and tech, the nation is turning into a prime destination for innovative startups.

Can health stakeholders be friends without being captives?

Agency leaders go slow in weighing changes to DTC ads and off-label marketing.

Our annual look at the drug industry's pipeline-the progress and the setbacks-puts my thoughts on those people driving new science behind the scenes in pharmaceutical research.

The five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.

A potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.

A deep dive into the outlook and implications from the UK’s recently unveiled life sciences blueprint for a post-Brexit world.

Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.

As the global reputation of neighboring pharma giants Switzerland and Germany continues to soar, Austria too is on the move, with the ambition of becoming a real driver and shaper of global medical innovation rather than merely just a link in the chain.

Click the title above to open the Pharmaceutical Executive November 2017 issue in an interactive PDF format.